The congress begins with two sets of parallel education sessions covering fundamental topics ahead of the main congress. Education Session 1 explores new vector design (1a) and therapeutic strategies ...
Explore the diverse streams that Cell and Gene Therapy International Europe 2026 has to offer, located at the Hotel Palace Berlin (Berlin, Germany) from 3–5 November 2026. This year, the Cell and Gene ...
The Cell & Gene Meeting on the Mesa, organized by the Alliance for Regenerative Medicine (DC, USA), addresses current challenges in the commercialization of cell and gene therapies. The conference ...
Air-liquid interface in vitro lung cell models more closely mimic in vivo morphology and physiological processes than traditional cell culture systems, making them beneficial for bridging experimental ...
Explore 2026's billion-dollar cell and gene therapy acquisitions, including in vivo CAR-T programs, epilepsy cell therapies, and in vivo gene placement systems. The cell and gene therapy landscape is ...
Diving into the intricate world of CAR-T cell therapy, Bita Sahaf shares insights from her work at the Cancer Correlative Science Unit in the Stanford Center for Cancer Cell Therapy (CA, USA). In this ...
This article explores the creation of Good Manufacturing Practice-compliant workflows for producing induced pluripotent stem cells and explores the strict quality and consistency standards set by Good ...
The FDA has placed a clinical hold on RGX-111 and RGX-121 after a patient in REGENXBIO’s Phase I/II trial of RGX-111 developed an intraventricular CNS tumor. An investigation into whether this serious ...
This week: Syntax Bio (IL, USA) announced the expansion of its Series A funding round, VectorBuilder (IL, USA) and MaxCyte (MD, USA) announced a strategic partnership to develop a novel gene delivery ...
Automated magnetic bead-based purification systems are transforming CAR T-cell development by streamlining critical workflows and reducing hands-on time by up to 80% while maintaining or exceeding ...
This week: the US Food and Drug Administration (FDA; MD, USA) cleared an Investigational New Drug (IND) application for a gene therapy indicated to treat an ultra-rare and fatal pediatric ...
This poster outlines a GMP manufacturing process for the creation of human induced pluripotent stem cells for use in allogeneic cell therapy applications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results